Editor’s Note: Last weekend, I caught up with Chief Income Strategist Marc Lichtenfeld at The Oxford Club’s 23rd Annual Investment U Conference in St. Petersburg, Florida.
Catch our conversation below…
– Rachel Gearhart, Associate Franchise Publisher
In this week’s special edition of State of the Market, Chief Income Strategist Marc Lichtenfeld sat down with Associate Franchise Publisher Rachel Gearhart to tackle a tough question…
After pharmaceutical companies’ run higher in the wake of positive COVID-19 news, has the ship sailed for biotech investors?
Now the sector, as represented by the iShares Nasdaq Biotechnology ETF (Nasdaq: IBB), has taken a dive, giving back its gains from earlier in the year.
But rather than the end of an epic run, Marc sees it as a buying opportunity.
It may be too late to get in on the biotech sector’s COVID-19 run-up…
But something even bigger is on the way.
The technology that was used to develop safe and effective COVID-19 vaccines – messenger RNA (mRNA) technology, a kind of gene therapy – has a host of other uses.
For years, it has been studied as a response to conditions like cancer and heart disease. It has the potential to save 10 million lives in the next decade.
And even now, its use in vaccine development has brought it to the forefront. The technology is attracting investor attention like never before.
After sharing his thoughts on the impending mRNA revolution, Marc reveals the three top qualities he looks for in a biotech company.
Don’t miss his sharp insights. Click here to watch this week’s episode of State of the Market.